Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
4.75 (1y: -22%)
Market Cap 86.69 M P/E(ttm) 14.10
Enterprise Value 20.89 M P/B 1.00
CPIX- NAS (USA)
Cumberland Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$4.75
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 16.293
CPIX's Cash to Debt is ranked higher than
57% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. CPIX: 16.293 )
CPIX' s 10-Year Cash to Debt Range
Min: 1.16   Max: 19.7
Current: 16.29
1.16
19.7
Equity to Asset 0.773
CPIX's Equity to Asset is ranked higher than
80% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. CPIX: 0.773 )
CPIX' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.8
Current: 0.77
0.05
0.8
Interest Coverage No Debt
CPIX's Interest Coverage is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. CPIX: No Debt )
CPIX' s 10-Year Interest Coverage Range
Min: 4   Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 5.99
M-Score: -1.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 18.10
CPIX's Operating margin (%) is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. CPIX: 18.10 )
CPIX' s 10-Year Operating margin (%) Range
Min: 7   Max: 24
Current: 18.1
7
24
Net-margin (%) 12
CPIX's Net-margin (%) is ranked higher than
78% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. CPIX: 12 )
CPIX' s 10-Year Net-margin (%) Range
Min: 5.4   Max: 24.7
Current: 12
5.4
24.7
ROE (%) 6.8
CPIX's ROE (%) is ranked higher than
62% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. CPIX: 6.8 )
CPIX' s 10-Year ROE (%) Range
Min: 3.2   Max: 39.6
Current: 6.8
3.2
39.6
ROA (%) 5.9
CPIX's ROA (%) is ranked higher than
75% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. CPIX: 5.9 )
CPIX' s 10-Year ROA (%) Range
Min: 2.7   Max: 19.2
Current: 5.9
2.7
19.2
ROC (Joel Greenblatt) (%) 94.50
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. CPIX: 94.50 )
CPIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 66.3   Max: 98.8
Current: 94.5
66.3
98.8
Revenue Growth (%) 0.8
CPIX's Revenue Growth (%) is ranked higher than
76% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. CPIX: 0.8 )
CPIX' s 10-Year Revenue Growth (%) Range
Min: 0.8   Max: 33.9
Current: 0.8
0.8
33.9
EBITDA Growth (%) 8
CPIX's EBITDA Growth (%) is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.35 vs. CPIX: 8 )
CPIX' s 10-Year EBITDA Growth (%) Range
Min: -5.4   Max: 76.9
Current: 8
-5.4
76.9
EPS Growth (%) 15.3
CPIX's EPS Growth (%) is ranked higher than
64% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. CPIX: 15.3 )
CPIX' s 10-Year EPS Growth (%) Range
Min: -15.9   Max: 24.7
Current: 15.3
-15.9
24.7
ยป CPIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CPIX Guru Trades in Q2 2012

Jim Simons 244,645 sh (+23.37%)
» More
Q3 2012

CPIX Guru Trades in Q3 2012

Jim Simons 266,900 sh (+9.1%)
» More
Q4 2012

CPIX Guru Trades in Q4 2012

Jim Simons 261,993 sh (-1.84%)
» More
Q1 2013

CPIX Guru Trades in Q1 2013

John Rogers 537,021 sh (New)
Jim Simons 242,270 sh (-7.53%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/E(ttm) 14.10
CPIX's P/E(ttm) is ranked lower than
297619% of the 336 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.80 vs. CPIX: 14.10 )
CPIX' s 10-Year P/E(ttm) Range
Min: 12.4   Max: 116
Current: 14.1
12.4
116
P/B 1.00
CPIX's P/B is ranked lower than
238095% of the 420 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.51 vs. CPIX: 1.00 )
CPIX' s 10-Year P/B Range
Min: 0.92   Max: 4.61
Current: 1
0.92
4.61
P/S 1.90
CPIX's P/S is ranked higher than
65% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. CPIX: 1.90 )
CPIX' s 10-Year P/S Range
Min: 1.65   Max: 6.82
Current: 1.9
1.65
6.82
PFCF 34.00
CPIX's PFCF is ranked lower than
411522% of the 243 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.36 vs. CPIX: 34.00 )
CPIX' s 10-Year PFCF Range
Min: 12.69   Max: 1432
Current: 34
12.69
1432
EV-to-EBIT 2.1
CPIX's EV-to-EBIT is ranked lower than
273224% of the 366 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.66 vs. CPIX: 2.1 )
CPIX' s 10-Year EV-to-EBIT Range
Min: 1.3   Max: 43.2
Current: 2.1
1.3
43.2
PEG 3.6
CPIX's PEG is ranked lower than
606060% of the 165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. CPIX: 3.6 )
CPIX' s 10-Year PEG Range
Min: 2.27   Max: 29.8
Current: 3.6
2.27
29.8
Shiller P/E 19.5
CPIX's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. CPIX: 19.5 )
CPIX' s 10-Year Shiller P/E Range
Min: 16.26   Max: 31.36
Current: 19.5
16.26
31.36

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 1.5
CPIX's Price/Net Cash is ranked lower than
751879% of the 133 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. CPIX: 1.5 )
CPIX' s 10-Year Price/Net Cash Range
Min: 1.4   Max: 5.2
Current: 1.5
1.4
5.2
Price/Net Current Asset Value 8.5
CPIX's Price/Net Current Asset Value is ranked lower than
255754% of the 391 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.80 vs. CPIX: 8.5 )
CPIX' s 10-Year Price/Net Current Asset Value Range
Min: 7.9   Max: 25.6
Current: 8.5
7.9
25.6
Price/Tangible Book 1.2
CPIX's Price/Tangible Book is ranked lower than
257732% of the 388 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. CPIX: 1.2 )
CPIX' s 10-Year Price/Tangible Book Range
Min: 1.1   Max: 3.8
Current: 1.2
1.1
3.8
Price/DCF (Projected) 0.8
CPIX's Price/DCF (Projected) is ranked lower than
624999% of the 160 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. CPIX: 0.8 )
CPIX' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1
Current: 0.8
0.7
1
Price/Median PS Value 0.7
CPIX's Price/Median PS Value is ranked lower than
243902% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. CPIX: 0.7 )
CPIX' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.2
Current: 0.7
0.6
2.2
Price/Graham Number 0.9
CPIX's Price/Graham Number is ranked lower than
324675% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. CPIX: 0.9 )
CPIX' s 10-Year Price/Graham Number Range
Min: 0.8   Max: 3.7
Current: 0.9
0.8
3.7
Earnings Yield (Greenblatt) 47.10
CPIX's Earnings Yield (Greenblatt) is ranked lower than
277008% of the 361 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. CPIX: 47.10 )
CPIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 75.7
Current: 47.1
2.3
75.7
Forward Rate of Return (Yacktman) 6.78
CPIX's Forward Rate of Return (Yacktman) is ranked lower than
704225% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.10 vs. CPIX: 6.78 )
CPIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.7   Max: 11.6
Current: 6.78
4.7
11.6

Business Description

Cumberland Pharmaceuticals Inc. was incorporated in Tennessee on January 6, 1999. The Company is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 100 sales representatives and managers as of March 1, 2012. Its products include: Acetadote (r), Kristalose(r), Caldolor(r), Hepatoren. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:CBJ.Germany
ยป More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial